Carregant...
Is there a room for immune checkpoint inhibitors in early stage non-small cell lung cancer?
Early non-small cell lung cancer (NSCLC) represents 16% of all new NSCLC at diagnosis with a 5-year survival rate of about 60%. Surgical intervention and adjuvant platinum-based chemotherapy represent the cornerstone treatments, but no significant advances have been achieved since several decades in...
Guardat en:
| Publicat a: | J Thorac Dis |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
AME Publishing Company
2018
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5994500/ https://ncbi.nlm.nih.gov/pubmed/29951294 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/jtd.2018.01.81 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|